StockData
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Evommune, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.27+0.10 (+1.93%)

Close on Oct 19, 2026

Market cap
$190.43M
P/E (TTM)
–
Dividend yield
–

SEC filings

20 of Evommune's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KOct 1, 2026Oct 1, 2026SEC EDGAR
Current report8-KSep 23, 2026Sep 23, 2026SEC EDGAR
Current report8-KSep 15, 2026Sep 15, 2026SEC EDGAR
Current report8-KSep 8, 2026Sep 9, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 6, 2026SEC EDGAR
Current report8-KAug 6, 2026Aug 6, 2026SEC EDGAR
Current report8-KJul 29, 2026Jul 30, 2026SEC EDGAR
Current report8-KJun 29, 2026Jun 29, 2026SEC EDGAR
Current report8-KJun 2, 2026Jun 2, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 7, 2026SEC EDGAR
Current report8-KMay 7, 2026May 7, 2026SEC EDGAR
Proxy statementDEF 14AApr 21, 2026Apr 21, 2026SEC EDGAR
Current report8-KApr 13, 2026Apr 13, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 5, 2026SEC EDGAR
Current report8-KMar 5, 2026Mar 5, 2026SEC EDGAR
Current report8-KFeb 12, 2026Feb 13, 2026SEC EDGAR
Current report8-KFeb 10, 2026Feb 10, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Dec 11, 2025SEC EDGAR
Current report8-KDec 11, 2025Dec 11, 2025SEC EDGAR
Current report8-KNov 7, 2025Nov 7, 2025SEC EDGAR